Indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion. Brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
The recommended dose is one drop of Betafree in the affected eye(s) twice daily.
Hypersensitivity to the active substance(s) or to any of the excipients, Neonates and infants under the age of 2 years.
Potential for sulfonamide hypersensitivity reactionsbecause of the brinzolamide tartrate component. Potential for corneal endothelium cell loss. Severe renal impairment may limit the metabolism of thebrinzolamide tartrate component.If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation. Caution incorneal edema patients.Betafree is not recommended in severe renal impairment.Contact lenses should be removed during instillation.
There are no adequate and well-controlled studies in pregnant women, nursing woman. Safety and effectiveness in infants below the age of two years have not been established